Ionis' Dawnzera Gets EU Approval for Hereditary Angioedema

Core Insights - The European Commission has approved Dawnzera (donidalorsen) for preventing recurrent attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older [1] Group 1: Approval and Market Impact - The approval was anticipated following a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency in November [2] - Dawnzera was previously approved by the FDA in the United States in August last year for HAE prophylaxis [2] - Ionis is set to receive a $15 million milestone payment from Otsuka Pharmaceutical following the EU approval and can earn tiered royalties of up to 30% on net product sales [3] - Ionis shares increased by approximately 2.5% in response to the EU approval, with a notable 130.5% rise over the past year compared to the industry's 3.3% decline [3] Group 2: Clinical Data and Efficacy - The EU approval of Dawnzera was supported by data from phase III OASIS-HAE and OASISplus studies, demonstrating significant efficacy and safety [4] - The OASISplus study indicated a 94% overall reduction in the mean monthly attack rate at one year for patients treated with Dawnzera [4] Group 3: Product Details - Dawnzera is an RNA-targeted preventive therapy designed to reduce plasma prekallikrein production, which triggers HAE attacks [8] - It is administered via subcutaneous injections with long dosing intervals of four to eight weeks, making it the first and only RNA-targeted therapy for HAE globally [8]